INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 121 filers reported holding INTRA CELLULAR THERAPIES INC in Q1 2017. The put-call ratio across all filers is 0.48 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $750 | +135.8% | 10,947 | +118.1% | 0.08% | +112.5% |
| Q2 2023 | $318 | -100.0% | 5,020 | -72.0% | 0.04% | -65.5% |
| Q2 2022 | $1,022,000 | +41.4% | 17,910 | +51.5% | 0.12% | +36.5% |
| Q1 2022 | $723,000 | -11.0% | 11,820 | -45.7% | 0.08% | -12.4% |
| Q3 2021 | $812,000 | +822.7% | 21,780 | +85.9% | 0.10% | +546.7% |
| Q3 2019 | $88,000 | -58.7% | 11,716 | -2.8% | 0.02% | -53.1% |
| Q2 2018 | $213,000 | -11.2% | 12,048 | +5.6% | 0.03% | -11.1% |
| Q1 2018 | $240,000 | -7.3% | 11,408 | -36.3% | 0.04% | -21.7% |
| Q4 2017 | $259,000 | +6.1% | 17,909 | +15.9% | 0.05% | +15.0% |
| Q3 2017 | $244,000 | +2.1% | 15,446 | -2.5% | 0.04% | -37.5% |
| Q4 2016 | $239,000 | – | 15,847 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DCF Advisers, LLC | 375,000 | $15,308,000 | 5.42% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 113,258 | $4,623,000 | 2.06% |
| Tri Locum Partners LP | 150,783 | $6,155,000 | 2.02% |
| COOPER/HAIMS ADVISORS, LLC | 61,116 | $2,495,000 | 1.64% |
| Vantage Consulting Group Inc | 226,670 | $9,252,000 | 1.61% |
| Nicholas Investment Partners, LP | 598,261 | $24,421,000 | 1.53% |
| Bellevue Group AG | 3,609,919 | $147,357,000 | 1.44% |
| GENERAL AMERICAN INVESTORS CO INC | 350,804 | $14,320,000 | 1.20% |
| Rhenman & Partners Asset Management AB | 429,728 | $17,541,000 | 1.19% |
| WASATCH ADVISORS LP | 6,506,789 | $265,607,000 | 1.08% |